Bladder cancer is a relatively small indication for Trodelvy, representing less than 10% of the drug’s sales, Gilead’s CFO ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

This week sees new and notable appointments at Royal London Ireland, Ipsen, Suir Engineering, Vantiva, Avacta and Nokia ...

From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS improvement.

In 2022, the global monoclonal antibodies market size was valued at USD 186 billion in 2021. The market is projected to ...

Scholar Rock (NASDAQ:SRRK – Free Report) had its price target increased by JPMorgan Chase & Co. from $18.00 to $31.00 in a ...

Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...